Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Solomon

Showing results (1711-1720 of 1,873) with videos related to

Pageof 188
Sort By:
JAMA Cardiology|March 29, 2025
Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical TrialShingo Matsumoto, Alasdair D Henderson, Pardeep S Jhund, et al.
JAMA Cardiology|May 21, 2025
Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical TrialMaria A Pabon, Orly Vardeny, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|March 6, 2020
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)Burkert Pieske, Carsten Tschöpe, Rudolf A de Boer, et al.
Journal of the American College of Cardiology|August 30, 2022
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
JAMA Cardiology|May 20, 2023
Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER TrialAlexander Peikert, Alvin Chandra, Mikhail N Kosiborod, et al.
Circulation|March 6, 2023
Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER TrialToru Kondo, Karola S Jering, C Jan Willem Borleffs, et al.
JAMA Cardiology|September 4, 2024
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical TrialMatthew M Y Lee, Ahmad Masri, Michael E Nassif, et al.
European Heart Journal|November 20, 2024
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney diseaseJohn W Ostrominski, Mats C Højbjerg Lassen, Brian L Claggett, et al.
European Journal of Heart Failure|March 15, 2024
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVERAlexander Peikert, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|July 15, 2019
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialAlvin Chandra, Muthiah Vaduganathan, Eldrin F Lewis, et al.
Pageof 188

Showing results (1711-1720 of 1,873) with videos related to

Sort By:
Pageof 188
JAMA Cardiology|March 29, 2025
Finerenone and Atrial Fibrillation in Heart Failure: A Secondary Analysis of the FINEARTS-HF Randomized Clinical TrialShingo Matsumoto, Alasdair D Henderson, Pardeep S Jhund, et al.
JAMA Cardiology|May 21, 2025
Finerenone in Heart Failure With Improved Ejection Fraction: The FINEARTS-HF Randomized Clinical TrialMaria A Pabon, Orly Vardeny, Muthiah Vaduganathan, et al.
European Journal of Heart Failure|March 6, 2020
How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)Burkert Pieske, Carsten Tschöpe, Rudolf A de Boer, et al.
Journal of the American College of Cardiology|August 30, 2022
Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection FractionJonathan W Cunningham, Muthiah Vaduganathan, Brian L Claggett, et al.
JAMA Cardiology|May 20, 2023
Association of Dapagliflozin vs Placebo With Individual Kansas City Cardiomyopathy Questionnaire Components in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the DELIVER TrialAlexander Peikert, Alvin Chandra, Mikhail N Kosiborod, et al.
Circulation|March 6, 2023
Patient Characteristics, Outcomes, and Effects of Dapagliflozin According to the Duration of Heart Failure: A Prespecified Analysis of the DELIVER TrialToru Kondo, Karola S Jering, C Jan Willem Borleffs, et al.
JAMA Cardiology|September 4, 2024
Aficamten and Cardiopulmonary Exercise Test Performance: A Substudy of the SEQUOIA-HCM Randomized Clinical TrialMatthew M Y Lee, Ahmad Masri, Michael E Nassif, et al.
European Heart Journal|November 20, 2024
Sodium-glucose co-transporter 2 inhibitors and new-onset diabetes in cardiovascular or kidney diseaseJohn W Ostrominski, Mats C Højbjerg Lassen, Brian L Claggett, et al.
European Journal of Heart Failure|March 15, 2024
Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVERAlexander Peikert, Muthiah Vaduganathan, Brian L Claggett, et al.
JACC. Heart Failure|July 15, 2019
Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF TrialAlvin Chandra, Muthiah Vaduganathan, Eldrin F Lewis, et al.
Pageof 188